| Overview |
| bs-8605R |
| HSV 1 Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Virus, Others |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from Herpes simplex virus 1 Neurovirulence factor ICP34.5 |
| 101-200/263 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| P08353 |
| Cytoplasm, Nucleus |
| Herpes simplex virus 1; Herpes Simplex Virus; Herpes Simplex Virus Type 1; HSV 1; Human herpesvirus 1; Human herpesvirus type 1;ICP34_HHV1F; Infected cell protein 34.5; Neurovirulence factor ICP34.5; protein gamma(1)34.5; RL1 |
| Contributes to HSV resistance to the antiviral effects of alpha/beta interferon. Recruits the serine/threonine-protein phosphatase PPP1CA/PP1-alpha to dephosphorylate the translation initiation factor eIF-2A, thereby counteracting the host shutoff of protein synthesis involving double-stranded RNA-dependent protein kinase EIF2AK2/PKR. Also down-modulates the host MHC class II proteins cell surface expression. Acts as a neurovirulence factor that has a profound effect on the growth of the virus in central nervous system tissue, probably through its ability to maintain an environment favorable for viral replication. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz